“As a research scientist who collaborates with clinicians, I found this conference invaluable to gain cutting edge knowledge of both clinical and research frontiers.”

• Home
• About the CCFA
• General Information
  • Conference Location
  • Key Dates
  • Accreditation
• Faculty
• Registration
  • Registration
  • Nurse Travel Grants
• Housing
• Abstracts
• Scientific Agenda
  • Planning Committee
  • Agenda at a Glance
  • Friday, December 10
  • Saturday, December 11
  • Sunday, December 12
• Symposia
• Exhibitor Information
• Supporters
• About Advances in IBD

• • Endorsed by:

  • 
  • 
  • 

Accreditation

Who Should Attend

This activity is intended for gastroenterologists, pediatric gastroenterologists, IBD sub-specialists, internists, gastroenterology nurses, gastroenterology mid-level providers, gastrointestinal surgeons, clinical researchers, and other health care professionals with an interest in the treatment of pediatric and adult patients with Inflammatory bowel disease.

Physicians: The University of Arkansas for Medical Sciences (UAMS) College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The UAMS College of Medicine designates this educational activity for a maximum of 18 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

It is the policy of the University of Arkansas for Medical Sciences (UAMS) College of Medicine to ensure balance, independence, objectivity, and scientific rigor in all sponsored or jointly sponsored educational activities. All individuals who are in a position to control the content of the educational activity (course/activity directors, planning committee members, staff, teachers, or authors of CME) must disclose all relevant financial relationships they have with any commercial interest(s) as well as the nature of the relationship. Financial relationships of the individual’s spouse or partner must also be disclosed, if the nature of the relationship could influence the objectivity of the individual in a position to control the content of the CME. The ACCME describes relevant financial relationships as those in any amount occurring within the past 12 months that create a conflict of interest. Individuals who refuse to disclose will be disqualified from participation in the development, management, presentation, or evaluation of the CME activity.

Nurses: This educational activity has been submitted to the Society of Gastroenterology Nurses and Associates, Inc, for approval. The Society of Gastroenterology Nurses and Associates, Inc, is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Physician Assistants: AAPA accepts certificates of participation for educational activities certifi ed for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit^TM from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 18 hours of Category 1 credit for completing this program.

Objectives

After attending this conference, clinicians and practitioners should be able to:

• Discuss the recent clinical trial data regarding the next generation of biologic therapies in IBD
• Discuss the reduction of the risk of undetected infections or misdiagnoses by increasing their frequency of testing for stool pathogens
• Describe methods to protect patients from adverse events when prescribing thiopurine-class drugs by testing more often for thiopurine methyltransferase (TPMT)
• Summarize current best practices related to treating children with IBD, especially the use of immunomodulators and biologics
• Discuss the indications for use, the mechanism for action, the outcomes and the patient education when a patient is using biological therapy
• Describe the indications for surgical and medical treatment of a patient with ulcerative colitis
• Discuss the choices from among 3 possible therapy options for a hospitalized child with steroid refractory ulcerative colitis
• Explain at least 1 argument for and 1 argument against targeted biopsies during cancer surveillance colonoscopy
• Identify at least 3 advanced management strategies to improve quality of care for patients with IBD
• Describe at least 1 argument for and 1 argument against making mucosal healing a standard therapeutic endpoint
• Discuss the selection of the most appropriate pharmacologic therapy for pregnant patients
• Restate at least 1 unanswered research question related to the basic science of IBD, especially genetics, immunology, or oncology

After attending this conference, basic scientists and researchers should be able to:

• Restate at least 3 unanswered research questions related to the basic science of IBD, especially genetics, immunology, microbiology, or oncology
• Discuss emerging basic science research in fi elds outside their own, especially genetics, immunology, microbiology, or oncology
• Summarize current research on the genetics of IBD in children
• Explain at least 1 recent advance in our understanding of autophagy, vasculature, or angiogenesis as they relate to IBD
• Clarify our current knowledge of immune system deregulation in IBD, especially the action of the IL-23/Th- 17 cytokine axis
• Appraise the frontiers of Scientific knowledge related to epithelial cells in intestinal inflammation and the role of stem cells in IBD